Federated Hermes Inc. Trims Stake in Relmada Therapeutics, Inc. (NASDAQ:RLMD)

Federated Hermes Inc. decreased its position in shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD) by 12.6% during the fourth quarter, Holdings Channel.com reports. The firm owned 99,839 shares of the company’s stock after selling 14,363 shares during the period. Federated Hermes Inc.’s holdings in Relmada Therapeutics were worth $413,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in RLMD. Stratos Wealth Partners LTD. purchased a new position in Relmada Therapeutics in the third quarter valued at $48,000. TD Asset Management Inc grew its position in shares of Relmada Therapeutics by 100.0% during the 3rd quarter. TD Asset Management Inc now owns 25,000 shares of the company’s stock valued at $75,000 after acquiring an additional 12,500 shares during the period. Silverarc Capital Management LLC purchased a new position in shares of Relmada Therapeutics in the 3rd quarter valued at about $300,000. Guild Investment Management Inc. raised its holdings in Relmada Therapeutics by 84.0% in the 3rd quarter. Guild Investment Management Inc. now owns 205,300 shares of the company’s stock worth $616,000 after purchasing an additional 93,750 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in Relmada Therapeutics by 4.4% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 270,396 shares of the company’s stock worth $1,119,000 after purchasing an additional 11,387 shares in the last quarter. 45.24% of the stock is owned by hedge funds and other institutional investors.

Relmada Therapeutics Trading Down 1.1 %

Shares of RLMD opened at $3.68 on Friday. The firm has a market cap of $111.03 million, a P/E ratio of -1.12 and a beta of 0.27. The stock’s 50 day moving average is $4.90 and its two-hundred day moving average is $4.00. Relmada Therapeutics, Inc. has a 12 month low of $2.36 and a 12 month high of $7.22.

Relmada Therapeutics (NASDAQ:RLMD) last released its quarterly earnings results on Tuesday, March 19th. The company reported ($0.84) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.04. Equities research analysts forecast that Relmada Therapeutics, Inc. will post -3.53 EPS for the current year.

Relmada Therapeutics Profile

Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder.